Mukaltin dispersible tablets with currants. 50mg, No. 20

Mukaltin dispersible tablets with currants. 50mg, No. 20; 'Acute and chronic diseases of the respiratory tract, accompanied by cough and the formation of difficult-to-separate high-viscosity sputum (including tracheobronchitis, obstructive bronchitis, bronchiectasis, pneumonia) - as part of complex therapy.

Adults and children from 12 years old inside 1-2 tablets 2-3 times a day before meals. The course of treatment is on average 7-14 days. Children can dissolve the tablet in 1/3 cup of warm water.

Active ingredient: marshmallow herb extract (mucaltin) - 50.0 mg;

excipients: calcium phosphate 2-substituted anhydrous (calcium hydrogen phosphate anhydrous) - 219.03 mg, crospovidone (crospovidone CE) - 102.82 mg, tartaric acid - 42.40 mg, black currant flavor * - 5.51 mg, calcium stearate - 4.24 mg.

* As part of the flavoring agent: natural flavoring agent, maltodextrin - 62.5%, gum arabic (E 414) - 26.5%, triacetin (E1518) - 6.5%.

• Hypersensitivity to the components of the drug,

• peptic ulcer of the stomach and duodenum,

• children under 12 years of age.

Pharmacological properties

Mukaltin is a mixture of polysaccharides from the herb marshmallow with expectorant properties. Thanks to reflex stimulation, it enhances the activity of the ciliated epithelium and the peristalsis of the respiratory bronchioles in combination with an increase in the secretion of the bronchial glands.

Pharmacokinetics

No data available.

Application during pregnancy and during breastfeeding

The use of the drug during pregnancy and during breastfeeding is possible on the recommendation of a doctor.

Side effect

Allergic reactions are possible, rarely - dyspeptic symptoms.

If you have any side effects indicated in the instructions or they are aggravated, or you notice any other side effects not listed in the instructions, inform your doctor.

Overdose

To date, no cases of overdose have been reported.

Interaction with other medicinal products

Mukaltin can be administered concurrently with other drugs used in the treatment of bronchopulmonary diseases.

Mukaltin should not be used concurrently with drugs containing codeine and other antitussive drugs, as this makes it difficult to cough up liquefied sputum.

If you are using the above or other drugs (including over-the-counter), consult your doctor before using Mukaltin.

Influence on the ability to drive vehicles, mechanisms

The use of the drug does not affect the ability to perform potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions (driving, working with moving mechanisms, the work of a dispatcher, operator).